Skip to content

Study · Non-randomized trial · n = 60 · 2001

1 result

Prevention of heterotopic ossification after total hip replacement: a prospective comparison of indomethacin and salmon calcitonin in 60 patients.

Günal I, Hazer B, Seber S, Göktürk E, Turgut A, Köse N

Acta orthopaedica Scandinavica1 Oct 2001Cited by 14 (Europe PMC)

PMID11728072 (opens in a new tab)DOI10.1080/000164701753532781 (opens in a new tab)PepBankPUB-11728072
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    After total hip replacement, heterotopic ossification occurred in fewer salmon calcitonin patients than indomethacin patients.

    In plain wordsAfter hip replacement, fewer patients developed abnormal bone formation with salmon calcitonin than with indomethacin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseHeterotopic ossification
    Study

    n = 60

    Comparator
    Indomethacin 100 mg/day
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3 MRC-U/kg/day · 14 daysAs given in this study (human).

    Measurements

    Heterotopic ossification
    2 patients
    calcitonin group, 30 patients
    Heterotopic ossification
    19 patients
    indomethacin group, 30 patients

    Source sentences

    Summary
    19 patients in the indomethacin group and 2 in the calcitonin group developed HO.
    2 context sentences
    Summary · context
    We did a prospective consecutive study of prophylaxis for heterotopic ossification (HO) comparing indomethacin (100 mg/day) and salmon calcitonin (3 MRC-U/kg/day) for 14 days.
    Summary · context
    Each group consisted of 30 patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.